Angle PLC
23 March 2005
For Immediate Release 23 March 2005
ANGLE plc
PROVEXIS LIMITED
Further to the announcement made on 18 February concerning the acquisition of
Provexis Limited by AIM listed Nutrinnovator Holdings PLC, good progress has
been made and discussions continue. ANGLE expects to release a further
announcement in due course.
For further information
ANGLE plc 01483 295830
Andrew Newland, Chief Executive
Dawson Buck, Deputy Chief Executive
Buchanan Communications 020 7466 5000
Richard Darby, James Strong
Notes to Editors
Founded in 1994, ANGLE is an international venture management and consulting
company focusing on the commercialisation of technology and the development of
technology-based industry. ANGLE creates, develops and advises technology
businesses on its own behalf and for its clients.
Provexis is a nutraceutical business founded by ANGLE in 2000 using its
established Progeny(R) process as a joint venture with the Rowett Institute, a
leading human nutrition research centre.
ANGLE is listed on AIM (AGL.L); further information can be found on
www.ANGLEplc.com
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.